Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Public ClinicalTrials.gov record NCT02052648. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
Study identification
- NCT ID
- NCT02052648
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Enrollment
- 160 participants
Conditions and interventions
Interventions
- Indoximod Drug
- Temozolomide Drug
- Bevacizumab Drug
- Stereotactic Radiation Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2014
- Primary completion
- Apr 17, 2018
- Completion
- Jun 19, 2019
- Last update posted
- Mar 26, 2024
2014 – 2019
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Eden Medical Center | Castro Valley | California | 94546 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| UC Irvine Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| University Cancer and Blood Center | Athens | Georgia | 30607 | — |
| Children's Healthcare of Atlanta | Atlanta | Georgia | 30342 | — |
| Augusta University | Augusta | Georgia | 30912 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| University of Kentucy | Lexington | Kentucky | 40536 | — |
| John Nasseff Neuroscience Institute | Minneapolis | Minnesota | 55407 | — |
| University of New Mexico Comprehensive Cancer Center | Albuquerque | New Mexico | 87131 | — |
| Wake Forest Baptist Health Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157 | — |
| Penn State Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Texas Oncology | Austin | Texas | 78705 | — |
| Huntsman Cancer Center | Salt Lake City | Utah | 84112 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02052648, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2024 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02052648 live on ClinicalTrials.gov.